l-4-cl-kyn
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2011 (NCT01483846)
Timeline
Indications
Mechanism of action
- Glutamate [NMDA] receptorANTAGONIST
Glutamate [NMDA] receptor antagonist
Antagonist of the glycin-site on GRIN1-subunits.
- Glutamate receptor ionotropic, NMDA 1 (GRIN1) ↗
- Glutamate receptor ionotropic, NMDA 2A (GRIN2A) ↗
- Glutamate receptor ionotropic, NMDA 2B (GRIN2B) ↗
- Glutamate receptor ionotropic, NMDA 2D (GRIN2D) ↗
- Glutamate receptor ionotropic, NMDA 3B (GRIN3B) ↗
- Glutamate receptor ionotropic, NMDA 2C (GRIN2C) ↗
- Glutamate receptor ionotropic, NMDA 3A (GRIN3A) ↗
- Glutamate (NMDA) receptor subunit zeta 1
- Glutamate [NMDA] receptor subunit epsilon 1
- Glutamate [NMDA] receptor subunit epsilon 2
- Glutamate [NMDA] receptor subunit 3A
- Glutamate [NMDA] receptor subunit epsilon 4
- Glutamate [NMDA] receptor subunit epsilon 3
- Glutamate NMDA receptor; GRIN1/GRIN2B
- Glutamate NMDA receptor; GRIN1/GRIN2A
- Ionotropic glutamate receptor NMDA 1/2C
- Ionotropic glutamate receptor NMDA 1/2D
- Glutamate NMDA receptor; GRIN1/GRIN2A/GRIN2B
- Glutamate receptor ionotropic, NMDA 1/2C/3B
Chemistry & pharmacology
Loading structure…
SMILES
Nc1cc(Cl)ccc1C(=O)CC(N)C(=O)O- Mol. weight
- 242.66 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL3545351 ↗
Also known as
- (2s)-2-amino-4-(2-amino-4-chlorophenyl)-4-oxobutanoic acid
- (2s)-2-amino-4-(2-amino-4-chlorophenyl)-4-oxobutanoic acid
- 3-(4-chloroanthraniloyl)-dl-alanine
- 4-chloro-dl-kynurenine
- 4-chlorokynurenine
- 4-chlorokynurenine
- 4-chlorokynurenine
- 4-chlorokynurenine
- av-101
- av-101
- av-101
- benzenebutanoic acid, alpha,2-diamino-4-chloro-gamma-oxo-, (+-)-
- l-4-chlorokynurenine
- l-4-chlorokynurenine
- l-4-cl-kyn
- l-4-cl-kyn
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03078322 | Phase 2 | Jun 1, 2017 | VistaGen Therapeutics, Inc. |
| NCT02484456 | Phase 2 | Jun 18, 2015 | National Institute of Mental Health (NIMH) |
| NCT01483846 | Phase 1 | Dec 1, 2011 | Cato Research, National Institute on Drug Abuse (NIDA), VistaGen Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| VistaGen Therapeutics, Inc. | For profit | 2 | 2 | 2 | 2011 |
| Cato Research | For profit | 1 | 0 | 1 | 2011 |
| National Institute of Mental Health (NIMH) | Government | 1 | 1 | 1 | 2015 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2011 |
4 organizations
Page 1 / 1